The SARS-CoV-2 pandemic has provided the stimulus for the rapid development of a variety of diagnostic testing methods. Initially these were deployed as screening tools to evidence spread of the virus within populations. The recent availability of vaccines against the virus and the need to better understand the parameters of post-infection protective immunity requires development of methods, suitable for use in the routine diagnostic laboratory, capable of characterising the viral immune response in greater detail. Such methods need to consider both cellular and humoral immunity. Toward this aim we have investigated use of a commercial multiplex assay (COVID Plus Assay, One Lambda), providing assessment of the SARS-CoV-2 response at structural level, and developed an in-house cell stimulation assay using commercially available viral peptides (Miltenyi). This paper reports our experience in use of these methods in extended investigation of a cohort of healthcare workers with prior screening results indicative of viral infection. The antibody response generated is shown to be both qualitatively and quantitatively different in different individuals. Similarly a recall response to SARS-CoV-2 antigen involving the T cell compartment can be readily demonstrated in recovered individuals but is of variable magnitude.

SARS-CoV-2 大流行为各种诊断测试方法的快速发展提供了刺激。最初，这些被部署为筛查工具，以证明病毒在人群中的传播。最近抗病毒疫苗的可用性以及更好地了解感染后保护性免疫参数的需要需要开发适用于常规诊断实验室的方法，能够更详细地描述病毒免疫反应的特征。这些方法需要同时考虑细胞免疫和体液免疫。为实现这一目标，我们研究了商业多重检测（COVID Plus 检测，One Lambda）的使用，在结构水平上提供对 SARS-CoV-2 反应的评估，并使用市售的病毒肽 (Miltenyi) 开发了一种内部细胞刺激试验。本文报告了我们使用这些方法对一组医护人员进行扩展调查的经验，这些医护人员先前的筛查结果表明存在病毒感染。所产生的抗体反应在不同个体中显示出定性和定量上的差异。同样，在康复个体中很容易证明对涉及 T 细胞区室的 SARS-CoV-2 抗原的回忆反应，但程度不同。所产生的抗体反应在不同个体中显示出定性和定量上的差异。同样，在康复个体中很容易证明对涉及 T 细胞区室的 SARS-CoV-2 抗原的回忆反应，但程度不同。所产生的抗体反应在不同个体中显示出定性和定量上的差异。同样，在康复个体中很容易证明对涉及 T 细胞区室的 SARS-CoV-2 抗原的回忆反应，但程度不同。